Pyxis Oncology (NASDAQ:PYXS) Earns Buy Rating from HC Wainwright

Pyxis Oncology (NASDAQ:PYXS - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright's price target suggests a potential upside of 313.22% from the stock's current price.

Separately, Royal Bank of Canada restated an "outperform" rating and set a $8.00 price target on shares of Pyxis Oncology in a research note on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Pyxis Oncology currently has an average rating of "Moderate Buy" and a consensus target price of $9.00.

Pyxis Oncology Trading Up 9.0%

Shares of PYXS stock opened at $1.21 on Monday. The firm has a market capitalization of $74.96 million, a P/E ratio of -1.17 and a beta of 1.15. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.39. The firm's fifty day simple moving average is $1.05 and its 200 day simple moving average is $1.62.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06). Equities research analysts anticipate that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds have recently made changes to their positions in the business. Millennium Management LLC lifted its stake in Pyxis Oncology by 53.8% during the fourth quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock worth $4,650,000 after purchasing an additional 1,043,228 shares during the period. Ridgeback Capital Investments L.P. acquired a new position in shares of Pyxis Oncology in the 4th quarter worth approximately $560,000. Pier 88 Investment Partners LLC lifted its position in shares of Pyxis Oncology by 296.6% during the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock worth $383,000 after buying an additional 292,370 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in shares of Pyxis Oncology by 57.2% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company's stock worth $939,000 after buying an additional 219,100 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pyxis Oncology in the 4th quarter valued at $228,000. Institutional investors and hedge funds own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.